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To retrospectively evaluate the incidence of tumour cell contamination of peripheral blood stem cell (PBSC) collections and to
correlate these data with the clinical outcome after high-dose chemotherapy (HDCT) with stem cell rescue in patients with a high-
risk Ewing tumour. Peripheral blood stem cell collections obtained from 171 patients were analysed. Tumour contamination was
assessed by reverse transcriptase–polymerase chain reaction (RT–PCR). The files of 88 patients who underwent HDCT followed by
PBSC reinfusion were reviewed in detail, and their outcome compared to the PBSC RT–PCR results. Seven of 88 PBSC collections
(8%) contained tumour cells as detected by RT–PCR. Peripheral blood stem cells were collected after a median of five cycles of
chemotherapy. No clinical factor predictive of tumour cell contamination of PBSC harvest could be identified. Event-free survival
(EFS) and overall survival (OS) of the whole study population were 45.3 % and 51.8 % at 3 years from the date of the graft,
respectively. Forty-five patients relapsed with a median time of 15 months after graft, only four of whom had tumour cell
contamination of the PBSC harvest. Tumour cell contamination of PBSC collection is rare and does not seem to be associated with a
significantly poorer EFS or OS in this high-risk population.
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Ewing tumours (ET) represent the second most common primary
bone malignancy and account for 4% of childhood and adolescent
malignancies. They are neoplasms with aggressive local and
metastatic behaviour, most often presenting as bone or less
frequently as soft tissue masses.
These tumours are characterised by a specific tumour cell
marker consisting of a balanced chromosomal translocation
involving chromosome 22 and chromosome 11, or less frequently,
chromosome 21, 2, 7, or 17. These balanced translocations lead
to the fusion of the EWS gene on chromosome 22 to members of
the ETS family of transcription factor genes FLI, ERG,o rFEV in
approximately 87%, 10%, and less than 1% of tumours, or ETV1 or
E1AF in rare cases, respectively (Turc-Carel et al, 1983; Delattre
et al, 1992; Zucman et al, 1993; Sorensen et al, 1994; Jeon et al,
1995; Kaneko et al, 1996; Peter et al, 1997; Kovar, 1998). These
fusion genes are transcribed in tumour cells and resulting
chimaeric transcripts can be detected by reverse transcriptase–
polymerase chain reaction (RT–PCR). Whereas cytogenetic
analysis is technically difficult and its results often obtained very
late, the search of the ET-specific fusion transcript by RT–PCR is a
rapid, specific, and sensitive (1/10
6 cells) diagnostic test and can
also be applied for the detection of minimal disease in peripheral
blood (PBL) and bone marrow (BM) (Delattre et al, 1994).
In ET, prognostic factors include age, primary site, and tumour
volume, the presence of metastases at diagnosis detected by
conventional methods and histological response to induction
chemotherapy (Cotterill et al, 2000; Paulussen et al, 2001; Jenkin
et al, 2002). Bone marrow micrometastases and circulating tumour
cells detected by RT–PCR were also recently reported as
prognostic factors (Schleiermacher et al, 2003). Prognosis of ET
remains poor, with 5-year relapse-free survival of 55 to 65% in
patients with localised disease and not exceeding 25% in primary
metastatic disease. Survival at 5 years after relapse is less than 20%
(Cotterill et al, 2000; Paulussen et al, 2001; Jenkin et al, 2002).
Treatment of ET requires a combination of multi-agent
chemotherapy because of the marked propensity for dissemination
of the tumour and on the other hand surgery and/or radiotherapy
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sto ensure the most effective local control. Several reports, mainly
in children, have suggested that some patients with high-risk
ET may benefit from high-dose chemotherapy (HDCT) followed by
autologous stem cell rescue (Burdach et al, 1993; Ladenstein et al,
1995; Burdach and Jurgens, 2002). The patient’s stem cells are
usually harvested after induction chemotherapy when complete
remission (CR) or very good partial remission (PR) is achieved.
Previous studies on small series of patients with ET have shown
that tumour cells might contaminate peripheral sites, including
autologous stem cell products from the patient (Toretsky et al,
1995; Leung et al, 1998; Fischmeister et al, 1999; Thomson et al,
1999; Montanaro et al, 1999; Yaniv et al, 2004). Data on the
incidence and prognostic value of tumour cell contamination of
peripheral blood stem cell (PBSC) collections have been con-
troversial.
The purpose of this study was to retrospectively evaluate the
incidence of tumour cell contamination of PBSC collections
detected by RT–PCR in a large series of patients with a high-
risk ET and to correlate these data with the clinical outcome after
HDCT with stem cell rescue.
PATIENTS AND METHODS
Samples
The initial study cohort consisted of all patients treated for ET in
French centres for whom a sample of a PBSC could be analysed at
the laboratory between February 1992 and December 2003.
These PBSC collections were obtained by CD34þ cell mobilisation
with concomitant chemotherapy and granulocyte-stimulating
factor (GCSF) or after priming with GCSF alone. All samples were
received at the laboratory in less than 24h following sampling. The
search for the EWS/FLI or EWS/ERG fusion transcripts was
performed by RT–PCR as described previously (Peter et al, 1995,
2001). In brief, RNA was isolated using the Trizole extraction kit,
reverse transcribed using the GeneAmp RNA PCR kit and
subjected to PCR in search of specific fusion transcript according
to a previously described nested PCR amplification procedure
between 1992 and 1998 and a real-time PCR procedure between
1999 and 2003 (Peter et al, 1995, 2001). The quality of RNA was
controlled by a test amplification of the ubiquitously expressed
EWS gene with identical PCR conditions, as published previously
(Delattre et al, 1994; Fagnou et al, 1998; Peter et al, 2001). In case
of PBSC collected over different days for the same patient, samples
were analysed separately but one single positive sample was
sufficient to consider positivity for the entire graft.
The search for tumour cells in PBSC samples was performed at
time of harvesting and required no additional sampling. In no
instance did the results influence therapeutic decisions. According
to the French law at the time of the study, no informed consent was
required for analysis of archived biologic material.
Patients
The initial cohort comprised 171 patients with a high-risk ET for
whom results of the search for an ET-specific fusion transcript in
a PBSC sample were interpretable. Of these, 25 patients were not
included in this study because they were enrolled in the
randomised arms of an ongoing clinical trial (EuroEwing 99).
Eighteen patients could not be included owing to a lack of
sufficient clinical information. Another 28 patients could not be
included because no molecular data of the tumour at diagnosis was
available. Thus, for 100 patients clinical history was reviewed in
detail. Twelve patients did not undergo HDCT, eight because of
early progressive disease (PD), two because there was finally no
indication, one because of cardiac insufficiency and the last one
because he refused. For none of the non-included patients had a
fusion transcript been found in PBSC collection.
Thus a total of 88 patients with a complete available data set for
whom PBSC were analysed by RT–PCR and who underwent HDCT
followed by PBSC reinfusion were included in this study. For these
patients the diagnosis of ET was confirmed by the presence of an
ET-specific fusion transcript in the primary tumour or in
peripheral sites.
Most of the patients (n¼71) were treated according to the
French Society of Paediatric Oncology (SFOP) EW 88, or EW
93-97 protocols or according to the nonrandomised arms of the
EuroEwing 99 protocol. These protocols include an induction
chemotherapy consisting of a combination of Doxorubicin and
Cyclophosphamide7Etoposide and Ifosphamide (EW 88/93-97),
or Vincristine, Ifosphamide, Doxorubicin and Etoposide (Euro-
Ewing 99). The other patients received induction chemotherapy
according to protocols used for adult patients consisting
essentially of various associations of the same drugs. Local
treatment consisted of surgery and/or radiotherapy.
Peripheral blood stem cell were obtained by cytapheresis. For
CD34þ cell mobilisation, conventional chemotherapy followed
by GCSF treatment or GCSF alone in steady state was used.
Conditioning treatment consisted of an association of Busulphan
and Melphalan in 75 patients and other types of HDCT
(Melphalan, Etoposide, Carboplatin, Ifosphamide, Thiotepa, and
Cyclophosphamide) in the 13 remaining patients.
At diagnosis, metastatic disease was searched for by pulmonary
CT scanner, technetium bone scintigraphy, and BM analysis.
Disease status was also evaluated at time of stem cell collection,
before HDCT and at the end of treatment. In case of search of
tumour cells in PBL or BM samples by RT–PCR, the results were
not known to clinicians and were not taken into account for
treatment stratification.
Statistical analysis
Correlation between clinical and molecular data was assessed
by using the Fisher’s exact test. Event-free survival (EFS) and
overall survival (OS), indicated with the standard deviation, were
estimated with the Kaplan–Meier method and compared by the
log-rank test. A P-value of less than 0.05 was considered to be
significant. Event-free survival was calculated from the day of
PBSC reinfusion until the date of last follow-up or event (tumour
progression or relapse). Overall survival was calculated from the
day of PBSC reinfusion to the last follow-up or disease- or toxicity-
related death.
RESULTS
Patients
The characteristics of the 88 patients with a high-risk ET who
underwent HDCT are shown in Table 1.
The median age was 15 years (range 1–49 years). The incidence
was higher in males than in females. Large tumours with a volume
over 200ml were observed in 36 of 71 evaluated patients (51%).
The primary tumour origin was most frequently in bone (76
patients; 86%). Metastases were present at diagnosis in 32 patients
(36%) with the lung being the most frequent site of metastatic
disease.
The indication for HDCT was metastatic disease at diagnosis in
32 patients (36%). Other indications for HDCT were poor response
to induction chemotherapy defined as less than 90% of necrosis at
surgery in 22 cases (25%) or clinical response less than 50% in case
of inoperability in four cases (5%), or personal choice of the
clinician in seven cases (8%). Finally, HDCT was indicated for
treatment of relapse in 23 cases (26%) (Figure 1).
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sTumour cell contamination of peripheral blood stem cell
collections
Only seven out of 88 PBSC harvests (8%) contained tumour cells as
detected by RT–PCR. Clinical variables associated with tumour
cell contamination of PBSC collection were searched for (Table 2).
Neither the presence of metastases or more specifically BM
metastases at diagnosis, nor the presence of circulating tumour
cells or BM micrometastases determined by RT–PCR at diagnosis,
nor the number of chemotherapy cycles before PBSC collection,
nor the status of disease at the time of PBSC collection, nor
the indication of HDCT (primary treatment or relapse) were
significantly correlated with the presence of contaminating tumour
cells in PBSC products. Likewise, no clinical factor predictive of
tumour cell contamination of PBSC harvest could be found in the
subgroup of patients with a primary indication of HDCT (n¼65).
The only patient with histologically diagnosed BM metastases at
the time of harvesting also scored positive by RT–PCR.
Patient characteristics of the group of patients with tumour cell
contamination of PBSC collections are shown in Table 3. In this
group of patients, for five patients PBSC was collected during
initial treatment whereas for the two others, PBSC was collected
after metastatic relapse. At the time of harvesting, two patients
were in CR, four in PR, and one in PD. Of the four patients in PR,
two patients achieved CR by the time of HDCT.
Of the seven PBSC RT–PCR-positive patients, one patient died
of complications immediately after HDCT, and four patients
relapsed in metastatic sites within 1 month, 2, 20, and 30 months
after stem cell rescue. Both patients whose indication of HDCT
was relapse, relapsed again after graft. Of the four patients who
relapsed, three have died and only one (patient 3) is still alive but
not free of disease. The two other patients who did not relapse
(patients 1 and 5) are alive in CR.
Clinical outcome of the study population (n¼88)
The median follow-up, calculated by the inverse Kaplan–Meier
method in order to take into account the real follow-up of all
patients, was 69 months (range 1–143 months). Of the total group
of 88 patients, 43 patients are alive, 38 in CR, one in SD, and four
in PD. Event-free survival and OS of the whole study population
are shown in Figure 2. They were 45.3% (711%) and 51.8%
(711%) at 3 years from the date of the graft, respectively. Patients
with tumour cell contamination of the PBSC collection did not
Table 1 Characteristics of patients with ET having undergone HDCT
followed by autologous stem cell rescue
Variable Total (n¼88)
Age in years (median and range) 15 (1–49)
Sex ratio (male/female) 54/34
Tumour volume (ml)
X200 36
o200 35
NE 17
Primary tumour site
Bone 76
Head 5
Trunk 44
Limbs 27
Soft tissue 12
Metastatic sites at diagnosis (n¼32)
Pulmonary 7
Bone 7
Bone marrow 2
Mixed (pulmonary and/or bone and/or BM) 15
Other 1
Treatment protocol
EW 88 4
EW 93-97 42
EE 99 (nonrandomised patients) 25
Other 17
Median number of chemotherapy cycles before PBSC collection 5 (2–10)
Global disease status at PBSC collection
CR 37
PR 45
SD 3
PD 1
NE 2
Conditioning regimen
Busulfan-Melphalan 75
Other 13
ET¼Ewing tumour; HDCT¼high-dose chemotherapy; BM¼bone marrow;
CR¼complete remission; PR¼partial remission; SD¼stable disease; PD¼pro-
gressive disease; NE¼not evaluated; PBSC¼peripheral blood stem cell.
n = 100
No HDCT
n = 12 
HDCT
n = 88 
Initial
metastatic
disease
n = 32
Poor
response to
ICT
n = 26
Relapse
n = 23
Other
n = 7 
Alive
n = 14* 
Alive
n = 13* 
Alive
n = 5* 
Alive
n = 11
Dead
n = 18
(3 DOT)
Dead
n = 13*
(3 DOT*)
Dead
n = 2
Dead
n = 12**
(1 DOT)
Figure 1 Indication of HDCT in 100 patients with a high-risk ET. HDCT: high-dose chemotherapy. ICT: induction chemotherapy. DOT: dead of toxicity.
*: Patients with tumour cell contamination of peripheral blood stem cell collection.
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spresent a statistically significant poorer EFS or OS (log-rank,
P¼0.39 and P¼0.20, respectively; Figure 3). Likewise, no
correlation between tumour cell contamination and poorer EFS
or OS could be found in the subgroup of 65 patients with an
indication of HDCT during primary treatment (log-rank, P¼0.9
and P¼0.72, respectively; figure not shown).
Of the 88 patients who underwent HDCT followed by autologous
stem cell rescue, 45 patients relapsed with a median time of 15
months after graft (range o1–33 months) and of those 45 patients,
38 died of tumour recurrence. Whereas recurrences occurred purely
locally in two out of the 41 patients with RT–PCR-negative harvest,
no purely local recurrences were observed in the four patients with
RT–PCR-positive harvest who relapsed (P¼1 . 0 ;T a b l e4 ) .O ft h ef o u r
patients with a positive harvest who relapsed, two relapsed in prior
metastatic sites and the two others in a single different metastatic site.
DISCUSSION
Tumour cell contamination in PBSC products that are reinfused
after potentially curative HDCT has become an important issue in
a number of haematological malignancies and solid tumours. In
this study, we have analysed tumour cell contamination of PBSC
collections in a large series of patients with ET and correlated these
findings with clinical outcome.
Our data show that the incidence of tumour cell contamination
of PBSC collections as determined by RT–PCR is very low (seven
out of the 88 patients included in this study; 8%) in this group of
patients with a high-risk ET. Taking into account all interpretable
results of PBSC analysis by RT–PCR, the incidence was even lower
(seven out of 171 cases; 4.1%), This finding is in contrast to the
frequency of PBSC contamination observed in some previously
published studies. In a recently published series all 11 patients had
contaminating tumour cells in their PBSC harvests (Yaniv et al,
2004). Two other studies have also reported a high incidence of
contamination by tumour cells, occurring in either marrow or
PBSC grafts of all five patients in both studies (Toretsky et al, 1995;
Leung et al, 1998). The incidence of tumour cell contamination of
PBSC products in the present study (8%) is more consistent with
the findings of three other studies which reported a proportion
of patients with tumour cell contamination of PBSC samples of
one out of 15 (6.7%), one out of nine (11.1%), and three out of 15
(20%), respectively (Fischmeister et al, 1999; Montanaro et al,
1999; Thomson et al, 1999). This important variability in incidence
of tumour cell contamination in PBSC collections in previous
reports might be due to different sensitivity and specificity of the
techniques of detection, to different times of harvesting and to
different disease status at the time of PBSC collection.
First, it is of concern that tumour cell detection by RT–PCR may
yield false-positive and/or false-negative results. In our study, to
Table 2 Clinical parameters of patients with RT–PCR-negative and -positive PBSC collection in the whole study population and in the patients with
indication of HDCT during primary treatment
HDCT (all indications) (n¼88) HDCT (indication during primary treatment) (n¼65)
RT–PCR PBSC collection RT–PCR PBSC collection
Variable Negative (n¼81) Positive (n¼7) Negative (n¼60) Positive (n¼5) P-value Fischer’s exact test
Initial metastases
Yes 31 1 31 1 NS
No 50 6 29 4
Initial BM metastases
Yes 11 0 11 0 NS
No 70 7 49 5
Initial BM micrometastases
Yes 6 0 4 0 NS
No 20 1 19 1
NE 55 6 37 4
Initial circulating tumour cells
Yes 2 1 1 1 NS
No 20 0 18 0
NE 59 6 41 4
Number of chemotherapy cycles before PBSC collection (median)
p5 cycles 43 5 24 3 NS
45 cycles 38 2 36 2
Metastases at the time of PBSC collection
Yes 33 3 19 1 NS
No 48 4 41 4
Disease status at the time of PBSC collection
CR 35 2 30 2 NS
No CR 44 5 30 3
NE 2 0 0 0
Indication of HDCT
Primary treatment 60 5 NS
Relapse 21 2
RT–PCR¼reverse transcriptase–polymerase chain reaction; PBSC¼peripheral blood stem cell; HDCT¼high-dose chemotherapy; BM¼bone marrow; CR¼complete
remission; NE¼not evaluated; NS¼not significant.
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savoid false-positive results generated by cross-contamination
linked to the use of PCR amplification techniques, several strict
precautions were taken. Samples were processed at different sites
for RNA isolation, PCR amplification, and electrophoresis of
PCR products and the two rounds of nested PCR amplification
were processed without opening the tube (Peter et al, 1995). The
observation that the type of fusion transcript was consistent
between primary tumour and PBSC collection provided a good
control for the specificity of the technique. Following the
introduction of real-time PCR in 1999, the risk of carry-over
contamination was even more reduced as no PCR products are
manipulated with this method (Peter et al, 2001). Moreover since
that time the GeneAmp RNA PCR kit has been used which contains
an enzyme (Uracil N-glycosylase) in order to degrade specifically
PCR products from previous PCR amplifications (Longo et al,
1990). To avoid false-negative results owing to an error during
the procedure resulting in degraded RNAs, an internal control
was established. The quality of RNA was controlled by a test
amplification of the ubiquitously expressed EWS gene with
identical PCR conditions. In the current study, a total of 34
patients were not included as no interpretable results of PBSC
RT–PCR analysis could be obtained owing to poor RNA quality.
Second, the time of harvesting might influence the incidence
of tumour cell contamination of PBSC collections. In a previous
study, one patient had a positive harvest after two and three cycles
of induction chemotherapy, whereas his harvest was negative after
four cycles (Toretsky et al, 1995). More recently, another study
reported that in two patients a first PBSC collection had had
tumour contamination detected by RT–PCR but subsequently
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Figure 2 EFS (A) and OS (B) of 88 patients with a high-risk ET after
stem cell rescue.
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et al, 1999). In our study, all PBSC collections were performed after
a median of five cycles of induction chemotherapy (a median of
four cycles in the group of patients with and five cycles in the
group of patients without tumour cell contamination of PBSC
collection), most likely contributing to the observed low incidence
of tumour cell contamination of PBSC collection. No positive
samples were observed in the group of patients treated according
to the EuroEwing 99 protocol (nonrandomised arms), which
consists of a more intensive induction chemotherapy (six cycles of
Vincristine, Ifosphamide, Doxorubicin, and Etoposide) in compari-
son to the previous EW 88 and EW 93–97 protocols. This could
suggest that more intensive induction chemotherapy might
eliminate circulating cells. However, owing to the small number
of positive samples and because of the inclusion of only
nonrandomised patients of the EuroEwing 99 protocol, the
relevance of these findings with regard to current clinical practice
needs to be interpreted with caution.
Third, the status of disease at the time of PBSC collection might
also influence the incidence of tumour cell contamination. In our
series, of the seven patients with positive harvest, only one patient
(patient 7) had BM disease at the time of harvesting and all
the patients with a negative harvest were free of disease in BM as
detected histologically at that time. Unfortunately for none of the
seven patients with tumour cell contamination of PBSC collection
in this study, samples of BM for the detection of micrometastases
at the time of PBSC collection could be studied. In a recently
published study, six out of the six PBSC-positive patients tested
had BM micrometastases at the time of harvesting (Yaniv et al,
2004). In two other studies tumour cells in BM detected by RT–
PCR were observed in two out of the three PBSC-positive patients
tested and in three out of the three PBSC-positive patients tested
but also in the only PBSC-negative patient, respectively (Toretsky
et al, 1995; Leung et al, 1998). Interestingly, in the two series with a
low incidence of tumour cell contamination of PBSC collection,
no cases of BM micometastases at the time of PBSC collection
were observed in the first and only one case in the second study
(Fischmeister et al, 1999; Thomson et al, 1999). This observation
might suggest that micrometastatic disease in BM should be sought
for before collecting PBSC.
Tumour cells present in autografts have been shown to be
associated with poor outcome in patients with haematological
malignancies or solid tumours. In a recently published study,
the presence of occult tumour cells in aphaeresis products was
correlated with worse EFS and OS in patients with high-risk
primary breast cancer and with worse EFS in patients with
metastatic breast cancer (Nieto et al, 2004). Another study
concluded that breast cancer patients with more than three
contaminating cells in their aphaeresis products represent a poor
prognosis group (Syme et al, 2003). In malignant germ-cell
tumours, the presence of contaminating tumour cells in PBSC
harvests seems to predict a poor EFS and OS in patients
undergoing HDCT and autologous PBSC reinfusion (Hildebrandt
et al, 2000). As demonstrated in a recently published trial,
myeloma patients with graft contamination of more than 4.5 10
5
plasma cells kg
 1 have a high risk of early disease progression after
HDCT (Vogel et al, 2005).
To date, the prognostic significance of tumour cell contamina-
tion of PBSC collection from patients with ET has only been
analysed in small series of patients. In a series of 11 patients, seven
out of the 11 patients with contaminated PBSC harvest relapsed
after graft and a possible correlation between the number of
contaminating cells in the harvest and relapse after transplantation
was suggested (Yaniv et al, 2004). In our study, no statistically
significant difference in EFS or OS after graft could be found
between patients with and without tumour cell contamination of
PBSC collection. Owing to the low incidence of tumour cell
contamination of PBSC collections, these results should be
interpreted with caution. Furthermore, the prognostic significance
of the contamination of PBSC collection might not be the same in
patients with different clinical indications for HDCT. However,
when the subgroup of patients with a primary indication of HDCT
was analysed separately, no significant correlation could be found
between tumour cell contamination of the PBSC collection and
poorer EFS or OS.
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Figure 3 EFS (A) and OS (B) of patients with RT–PCR-negative and
-positive harvest after stem cell rescue. In the RT–PCR-positive group, the
latest event consisting of a relapse occurring at 30 months following HDCT
has not been indicated intentionally.
Table 4 Outcome after graft in 88 patients with ET
Outcome after
graft
Negative PBSC
collection
(n¼81)
Positive PBSC
collection
(n¼7)
No relapse 40 3
Relapse 41 4
Median time (months) 16 (o1–33) 15 (o1–30)
Location
Local 2 0
Metastatic 31 4
Both 8 0
ET, Ewing tumour; PBSC¼peripheral blood stem cell.
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sThe role of reinfused contaminating tumour cells for
disease progression remains unclear. In our study, of the four
patients with a positive harvest who relapsed, two patients relapsed
in prior metastatic sites, indicating that remaining systemic
disease might have been the primary cause of relapse rather than
a direct effect of reinfusion of tumour cells. This suggests an
insufficient cytoreductive capacity of HDCT rather than a
direct effect of tumour cells contaminating the graft. Indeed, the
benefit of HDCT has been questioned especially for patients
with BM metastases (Oberlin et al, 2006). It might be possible that
PBSC contamination reflects only a greater overall tumour
burden, with reinfused cancer cells having no major role in
disease relapse. Prior analyses in advanced breast cancer have
suggested that contaminating tumour cells in PBSC collections
may be a marker of widespread micrometastatic disease rather
than a direct cause of recurrence after transplantation (Nieto et al,
2004). Furthermore, the biological significance of contaminating
tumour cells in PBSC collection remains to be established. Indeed,
two patients in our study did not relapse after graft and are still
in CR, which might suggest that the autograft did not contain
tumorigenic tumour cells with a metastatic potential. Several
investigators have performed qualitative tests on micrometastatic
tumour cells, including the determination of the viability and
growth potential of these cells and the assessment of the invasive
capacity in various solid tumours (Ross et al, 1993; Moss et al,
1994; Sharp et al, 1996). In ET, the oncogenic potential of tumour
cells detected by RT–PCR in PBSC collection, although likely,
remains to be proven.
In conclusion, our study shows that the incidence of tumour cell
contamination of PBSC collection from patients with high-risk ET
is low and that it does not seem to have an additional negative
impact on outcome in this population already at risk.
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